The μ-opioid receptor (MOR) is the primary target for opioid analgesics. MOR induces analgesia through the inhibition of second messenger pathways and the modulation of ion channels activity. Nevertheless, cellular excitation has also been demonstrated, and proposed to mediate reduction of therapeutic efficacy and opioidinduced hyperalgesia upon prolonged exposure to opioids. In this mini-perspective, we review the recently identified, functional MOR isoform subclass, which consists of six transmembrane helices (6TM) and may play an important role in MOR signaling. There is evidence that 6TM MOR signals through very different cellular pathways and may mediate excitatory cellular effects rather than the classic inhibitory effects produced by the stimulation of the major (7TM) isoform. Therefore, the development of 6TM and 7TM MOR selective compounds represents a new and exciting opportunity to better understand the mechanisms of action and the pharmacodynamic properties of a new class of opioids.
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The μ-opioid receptor (MOR) is the primary target for opioid analgesics. MOR induces analgesia through the inhibition of second messenger pathways and the modulation of ion channels activity. Nevertheless, cellular excitation has also been demonstrated, and proposed to mediate reduction of therapeutic efficacy and opioidinduced hyperalgesia upon prolonged exposure to opioids. In this mini-perspective, we review the recently identified, functional MOR isoform subclass, which consists of six transmembrane helices (6TM) and may play an important role in MOR signaling. There is evidence that 6TM MOR signals through very different cellular pathways and may mediate excitatory cellular effects rather than the classic inhibitory effects produced by the stimulation of the major (7TM) isoform. Therefore, the development of 6TM and 7TM MOR selective compounds represents a new and exciting opportunity to better understand the mechanisms of action and the pharmacodynamic properties of a new class of opioids.
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Introduction: biphasic cellular inhibitory and excitatory effects of MOR agonists
Opioids are the most frequently used and effective analgesics for the treatment of moderate to severe pain. Unfortunately, both acute and chronic use is frequently associated with a number of adverse side effects such as respiratory depression, nausea, constipation, itching, xerostomia, drowsiness, as well as physical and psychological addiction. In addition, the prolonged use of opioids may lead to reduced efficacy (tolerance) and a clinically significant problem of post-dosing opioidinduced hyperalgesia (OIH) (Ballantyne and Shin, 2008; Chu et al., 2008; Lee et al., 2011) . At a cellular level, MOR is a primary target for clinically used opioids, and MOR-induced analgesia is due to the initiation of presynaptic and/or postsynaptic inhibitory processes that decrease the electrical excitability, neurotransmitter release, and/or pro-nociceptive processes.
The canonical seven transmembrane (7TM) MOR is a member of the G-protein-coupled receptor (GPCR) family. MOR signaling involves activation of a pertussis toxin (PTX)-sensitive G-proteins (Gα i/o ). Receptor activation leads to the dissociation of the heterotrimeric G-protein complex: the release of the α subunit inhibits adenylyl cyclase, while the βγ subunit activates K + channels or inhibits voltage-gated Ca 2+ channels (VGCC) (Crain and Shen, 2000; North, 1986; Williams et al., 2001 ). MOR-mediated inhibition of VGCC on the central presynaptic terminals of primary afferent nociceptors is thought to be one of the primary mechanisms mediating the spinal analgesic effects of opiates. K + channel activation is a primary mechanism underlying the inhibitory actions of MOR on central nervous system neurons (Herz and Millan, 1990; Millan, 2002; Stanfa and Dickenson, 1995) . Similarly to the analgesic effects of opioids, tolerance and OIH are also manifested in both animals and human following acute or chronic 
